Electrotherapy Devices (TENS, EMS) in Louisiana

Therapeutic Neuromodulation Systems (TNMS) develops percutaneous electrical nerve stimulation (PENS) devices for non-pharmaceutical pain management, post-operative recovery, and opioid withdrawal management. The company's core technology is a wearable neurostimulator placed behind the ear that targets the vagal nerve and peripheral nerve endings to trigger endogenous release of pain-relieving substances such as endorphins. This mechanism reduces pain sensitivity, inflammation, and muscle tightness without pharmaceutical intervention. TNMS offers three integrated product lines: the MD Device for chronic and acute pain management; the POSP Device designed to minimize opioid dependence and accelerate surgical recovery; and The Morph, a specialized solution for managing opioid withdrawal symptoms. The devices are indicated for use in hospital, surgical, and clinical pain management settings as well as opioid detoxification programs. The company serves healthcare providers and patients seeking alternatives to pharmaceutical pain management and opioid-based therapies. Regulatory status and specific certifications (510(k), FDA clearance, ISO 13485) are not explicitly stated on the available website content but are typical requirements for such neurostimulation devices.

VasoCARE manufactures and distributes the Legacy® IPC, a lightweight (70 grams), wearable, silent intermittent pneumatic compression device designed for hospital-based DVT prophylaxis and prevention of hospital-acquired complications. The reusable Legacy® IPC system improves patient compliance above 80% and reduces DVT by over 60%, compared to traditional sequential compression devices (SCDs) which achieve only 48% compliance and 50% DVT reduction. The integrated Legacy APP monitoring station enables real-time clinical oversight of device performance and patient compliance without requiring sleeve removal and reapplication, freeing nursing staff for direct patient care. Clinical evidence demonstrates significant cost savings—approximately $130,000 annually per 1,000 hospital admissions—through prevention of hospital-acquired DVT, ventilator-associated pneumonia, and pressure injuries. VasoCARE also distributes Bio Compression's pneumatic compression therapy devices for outpatient management of edema, lymphedema, and venous stasis ulcers, and provides VeinOPlus® Vascular, a neuromuscular electrical stimulation device that enhances venous and arterial circulation for diabetic foot and venous ulcer prevention.